跳至主要内容
临床试验/EUCTR2014-004565-24-NL
EUCTR2014-004565-24-NL进行中(未招募)不适用

A Randomized, Single-blind, Propofol-controlled Phase III Study Evaluating the Efficacy and Safety of Remimazolam in General Anesthesia in Adult Patients Undergoing Cardiac Surgery, Including Follow-up Sedation in the Post-anesthesia Care Unit / Intensive Care Unit

PAION UK Limited0 个研究点目标入组 530 人开始时间: 2015年9月28日最近更新:
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
530

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Patients scheduled for major non-emergency cardiac surgery assumed to require more than 2 hours of maintenance of general anesthesia and to require the use of extracorporeal circulation, including coronary bypass(es), valve replacement(s) and associated procedures and on-pump minimal invasive surgery
  • Scheduled to receive mechanical ventilation via tracheal intubation (oropharyngeal or nasotracheal)
  • Age at least 18 years
  • Body Mass Index (BMI) 18 to = 40 kg/m2
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 265
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 265

排除标准

  • Re-do cardiac surgery
  • Surgical procedures that comprise the use of drugs and/or devices that are not approved for marketing
  • Severe tricuspidal insufficiency
  • Planned cooling below 32ºC
  • History of or planned stop of circulation, e.g. due to repair of type A dissection of aorta or removal of thrombi from pulmonary artery
  • Planned to receive epidural/spinal anesthesia together with general anesthesia
  • Evidence of uncontrolled hepatic, central nervous system, respiratory, or metabolic dysfunction, or other clinically significant findings at screening that, in the investigator’s or medical monitor’s opinion, should exclude them from the study.
  • Poorly controlled hypertension (e.g. systolic blood pressure =160 mmHg under antihypertensive medication at screening)
  • Severe renal insufficiency or end-stage renal disease (creatinine clearance below 30 mL/min or estimated glomerular filtration rate below 30 mL/min/1.73 m2).
  • Clinically uncontrolled coagulation abnormalities, or coagulation abnormalities not under adequate treatment
  • Scheduled for heart or lung transplantation
  • Infectious cardiac disorders (e.g. endocarditis, myocarditis)
  • Emergency surgery, status of shock or coma
  • Ejection fraction from left ventricle of less than 20%
  • Acute right heart failure

研究者

相似试验

进行中(未招募)
1 期
Clinical phase III study of the sedative remimazolam in general narcosis in adult patients undergoing heart surgery, including subsequent care in the post-anesthesia/intensive care unit, in order to evaluate the effects and safety of remimazolam.Anesthesia in adult patients undergoing cardiac surgery.MedDRA version: 18.1Level: LLTClassification code 10021722Term: Induction and maintenance anaesthesiaSystem Organ Class: 100000004865
EUCTR2014-004565-24-DEPAION UK Limited530
进行中(未招募)
1 期
Clinical phase III study of the sedative remimazolam in general narcosis in adult patients undergoing heart surgery, including subsequent care in the post-anesthesia/intensive care unit, in order to evaluate the effects and safety of remimazolam.Anesthesia in adult patients undergoing cardiac surgery.MedDRA version: 18.0Level: LLTClassification code 10021722Term: Induction and maintenance anaesthesiaSystem Organ Class: 100000004865
EUCTR2014-004565-24-BEPAION UK Limited530
进行中(未招募)
不适用
A Randomized, Single-Blind, Placebo-Controlled, Phase 2 Trial of the Safety, Immunogenicity, and Tolerability of Meningococcal Serogroup B (MnB) rLP2086 Vaccine at Doses of 60 µg, 120 µg, and 200 µg in Healthy Adolescents Aged 11 to 18 YearsThe test is a vaccine. The subjects are healthy adolescents.MedDRA version: 14.1Level: PTClassification code 10027202Term: Meningitis bacterialSystem Organ Class: 10021881 - Infections and infestations
EUCTR2008-007789-51-PLPfizer Inc715
进行中(未招募)
不适用
A clinical study to test the safety and immune response of a vaccine against a bacteria causing meningitis B at doses of 60 µg, 120 µg, and 200 µg in healthy adolescents aged 11 to 18 YearsPrevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MnB) in adolescents and young adults, aged 10 through 25 years.MedDRA version: 17.1Level: LLTClassification code 10004049Term: Bacterial meningitisSystem Organ Class: 100000004862
EUCTR2008-007789-51-Outside-EU/EEAWyeth Research Division of Wyeth Pharmaceuticals Inc.539
已完成
1 期
To evaluate safety and tolerability after multiple oral doses of AZD1656 in type 2 diabetes patients on top of metformi
CTRI/2009/091/000774AstraZeneca AB, 151 85 Södertälje, Sweden24